Welcome to our dedicated page for Nautilus Biotechnology SEC filings (Ticker: NAUT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Wondering how Nautilus Biotechnology’s R&D burn or insider confidence is trending? Most investors begin with the 10-K annual report or a fresh 10-Q quarterly earnings report, but the real challenge is extracting what matters about proteomics platform development, cash runway, and patent updates hidden inside hundreds of pages.
Stock Titan’s AI reads every Nautilus Biotechnology SEC filing the moment it hits EDGAR and delivers plain-English answers to questions people actually ask, such as “Nautilus Biotechnology insider trading Form 4 transactions” or “understanding Nautilus Biotechnology SEC documents with AI.” Our platform:
- Flags Form 4 insider transactions in real-time so you can track executive stock moves before the market reacts.
- Breaks down each 10-Q earnings report filing analysis into revenue cadence, R&D expense trends and liquidity highlights.
- Summarizes the annual report 10-K simplified, spotlighting milestones toward commercial launch of the proteome analysis system.
- Explains every 8-K material event—from strategic collaborations to equity raises—within minutes of filing.
- Maps the proxy statement executive compensation details to key talent retention metrics.
Whether you need “Nautilus Biotechnology Form 4 insider transactions real-time” alerts, a quick primer on chip-based proteomics from the latest S-1, or context around pipeline partnerships, our expert-trained AI turns dense disclosures into clear insights. Save hours, stay current, and make informed decisions with every Nautilus Biotechnology SEC document—explained simply.
Nautilus Biotechnology (NAUT) reported an insider share purchase on a Form 4. The company’s Chief Marketing Officer bought 4,000 shares of common stock on 11/06/2025 at $1.49 per share. Following the transaction, the officer beneficially owned 4,000 shares, held directly.
Nautilus Biotechnology (NAUT) regained Nasdaq listing compliance. The company received notice on November 3, 2025 that it meets Nasdaq Listing Rule 5550(a)(2) after its common stock closed at or above $1.00 per share for a minimum of ten consecutive business days. Nasdaq stated the matter is now closed.
Earlier in 2025, NAUT had fallen below the minimum bid-price requirement and was granted compliance periods through October 28, 2025, then transferred to The Nasdaq Capital Market on October 29, 2025 with additional time to cure. Regaining compliance supports the company’s continued listing on The Nasdaq Capital Market under the NAUT ticker.
Nautilus Biotechnology (NAUT) filed its Q3 2025 10‑Q, reporting continued development-stage operations with no product revenue and a narrower quarterly loss. Net loss was $13.6 million for the quarter and $45.2 million for the nine months. Operating expenses decreased to $15.5 million in Q3, driven by lower R&D ($9.6 million) and G&A ($5.9 million), reflecting cost optimizations and prior workforce reductions.
As of September 30, 2025, the company held $131.4 million in cash, cash equivalents, and short‑term investments, and stated these resources are sufficient to fund operations for at least the next twelve months. Total assets were $200.9 million and stockholders’ equity was $169.1 million. Interest income was $1.9 million in Q3, down year over year on lower balances and yields.
Nautilus remains in the collaboration phase for its proteomics platform and expects early access offerings in the first half of 2026 (including Tau assays) with a broader launch targeted for late 2026. Shares outstanding were 126,305,122 as of October 23, 2025.
Nautilus Biotechnology insider purchases increased Sujal Patel's stake. The filing shows the CEO, President, Secretary and a director acquired 116,500 shares on 09/05/2025 at a weighted average price of $0.6742 and 83,500 shares on 09/08/2025 at a weighted average price of $0.683, bringing his reported direct beneficial ownership to 10,341,721 shares. The filing also discloses indirect holdings of 1,814,035 shares held in the Sujal Patel 2020 Children\'s Trust and 5,280,476 shares held by PFV I, LLC, where he is manager. The form was signed by an attorney-in-fact on 09/09/2025.
Matthew B. Murphy, listed as General Counsel and Trustee of the Murphy Family Trust, reported transactions in Nautilus Biotechnology, Inc. (NAUT) on 09/04/2025.
He purchased 20,000 shares of Nautilus common stock at $0.6429 per share and disposed of 1,250 shares on the same transaction date. After the reported purchase, the filing shows beneficial ownership of 74,140 shares held indirectly through the Murphy Family Trust.
Form 4 overview: On 06/23/2025, Nautilus Biotechnology, Inc. (ticker NAUT) granted Director Melissa B. Epperly a new equity award.
- Security type: Non-qualified stock option (right to buy common stock).
- Shares underlying option: 45,000.
- Exercise price: $0.6951 per share.
- Term: Expires 06/23/2035 (10-year life).
- Vesting schedule: Monthly vesting in 12 equal instalments, subject to Ms. Epperly maintaining “Service Provider” status, as defined in the company’s 2021 Equity Incentive Plan.
- Post-transaction beneficial ownership (derivative form): 45,000 options held directly.
The filing reports no disposals or open-market purchases of common stock; the only activity is the A-coded (grant) issuance of the option. No Rule 10b5-1 trading plan is indicated. The form was signed on 06/24/2025 by attorney-in-fact Mathew B. Murphy.
Investor takeaway: This is a routine director compensation grant that minimally affects share count but incrementally aligns the director’s incentives with shareholder value creation.
The filing is a Form 4 dated 06/24/2025 reporting insider activity at Nautilus Biotechnology, Inc. (ticker NAUT). Director Matthew L. Posard was granted a stock option covering 45,000 common shares at an exercise price of $0.6951 per share. The option was issued on 06/23/2025, vests in twelve equal monthly installments as long as Mr. Posard remains a “Service Provider,” and expires on 06/23/2035. After the transaction, Mr. Posard beneficially owns 45,000 derivative securities, all held directly. No common shares were bought or sold on the open market; the filing reflects an incentive-based equity award only.
Form 4 snapshot: On 06/23/2025, Nautilus Biotechnology, Inc. (ticker NAUT) filed a Form 4 disclosing that director Matthew S. McIlwain received a new equity award.
- Instrument granted: Non-qualified stock option (right to buy common shares).
- Quantity: 45,000 option units.
- Exercise price: $0.6951 per share.
- Expiration: 06/23/2035 (10-year term).
- Vesting schedule: Subject to the director’s continued “Service Provider” status, one-twelfth (1/12) of the option vests monthly after the grant date, fully vesting over one year.
- Post-transaction holdings: McIlwain now beneficially owns 45,000 derivative securities (options) directly; no non-derivative share activity was reported.
- Transaction code: “A” (grant) – no open-market purchase or sale; zero cash proceeds reported.
The filing indicates routine board compensation designed to align the director’s incentives with shareholder returns. No shares were sold or purchased, and there is no indication of additional indirect ownership or Rule 10b5-1 trading plan usage. Overall, the disclosure is limited to a single option grant and does not introduce immediate dilution or cash flow impact for the company.
FAQ
What is the current stock price of Nautilus Biotechnology (NAUT)?
What is the market cap of Nautilus Biotechnology (NAUT)?
